STOCK TITAN

[SCHEDULE 13D/A] Galapagos NV SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

EcoR1 Capital files Amendment No. 3 to Schedule 13D on Galapagos NV (GLPG). The biotech-focused hedge fund and its founder Oleg Nodelman now report beneficial ownership of 8,714,522 ordinary shares/ADSs, equal to 13.22 % of the 65,897,071 shares outstanding (Form 20-F, 31 Dec 2024). The position is concentrated in EcoR1 Capital Fund Qualified, L.P. (8.19 m shares, 12.43 %) while EcoR1 Capital Fund, L.P. holds 0.52 m shares (0.79 %).
The shares were accumulated for an aggregate US$399.4 million; an additional US$293,693 in fees was paid to Citibank for converting ADSs into ordinary shares. EcoR1 and Mr Nodelman have shared voting and dispositive power over the entire stake.
Apart from updating share totals and cost, the filing makes no changes to the previously stated purpose of the investment or to any contracts, arrangements or relationships with the issuer. Exhibit 99.2 details trades executed in the past 60 days; no other transactions were disclosed.

EcoR1 Capital presenta l'Emendamento n. 3 al Modulo 13D riguardante Galapagos NV (GLPG). Il fondo hedge specializzato in biotecnologie e il suo fondatore Oleg Nodelman comunicano ora una partecipazione beneficiaria di 8.714.522 azioni ordinarie/ADS, pari al 13,22% delle 65.897.071 azioni in circolazione (Modulo 20-F, 31 dicembre 2024). La posizione è concentrata principalmente in EcoR1 Capital Fund Qualified, L.P. (8,19 milioni di azioni, 12,43%), mentre EcoR1 Capital Fund, L.P. detiene 0,52 milioni di azioni (0,79%).
Le azioni sono state accumulate per un totale di 399,4 milioni di dollari USA; inoltre, sono stati pagati 293.693 dollari USA in commissioni a Citibank per la conversione degli ADS in azioni ordinarie. EcoR1 e il signor Nodelman detengono il potere condiviso di voto e disposizione sull’intera partecipazione.
Oltre all’aggiornamento delle quantità di azioni e dei costi, il deposito non apporta modifiche allo scopo dell’investimento precedentemente dichiarato né a contratti, accordi o relazioni con l’emittente. L’Exhibit 99.2 dettaglia le operazioni effettuate negli ultimi 60 giorni; non sono state comunicate altre transazioni.

EcoR1 Capital presenta la Enmienda No. 3 al Schedule 13D sobre Galapagos NV (GLPG). El fondo de cobertura enfocado en biotecnología y su fundador Oleg Nodelman reportan ahora una propiedad beneficiaria de 8.714.522 acciones ordinarias/ADS, equivalente al 13,22 % de las 65.897.071 acciones en circulación (Formulario 20-F, 31 de diciembre de 2024). La posición está concentrada en EcoR1 Capital Fund Qualified, L.P. (8,19 millones de acciones, 12,43 %) mientras que EcoR1 Capital Fund, L.P. posee 0,52 millones de acciones (0,79 %).
Las acciones se acumularon por un total de 399,4 millones de dólares estadounidenses; se pagaron además 293.693 dólares en comisiones a Citibank por la conversión de ADS en acciones ordinarias. EcoR1 y el Sr. Nodelman tienen poder compartido de voto y disposición sobre toda la participación.
Además de actualizar los totales de acciones y el costo, la presentación no realiza cambios en el propósito previamente declarado de la inversión ni en contratos, acuerdos o relaciones con el emisor. El Anexo 99.2 detalla las operaciones ejecutadas en los últimos 60 días; no se divulgaron otras transacciones.

EcoR1 Capital이 Galapagos NV(GLPG)에 대해 스케줄 13D 수정안 3호를 제출했습니다. 생명공학 중심의 헤지펀드와 창립자 Oleg Nodelman은 현재 8,714,522 보통주/ADS를 실질 소유하고 있으며, 이는 65,897,071주 발행 주식의 13.22%에 해당합니다(2024년 12월 31일 기준, Form 20-F). 보유 지분은 EcoR1 Capital Fund Qualified, L.P.에 집중되어 있으며(819만 주, 12.43%), EcoR1 Capital Fund, L.P.는 52만 주(0.79%)를 보유하고 있습니다.
주식은 총 3억 9,940만 달러에 매입되었으며, ADS를 보통주로 전환하는 데 Citibank에 추가로 293,693달러의 수수료가 지급되었습니다. EcoR1과 Nodelman 씨는 전체 지분에 대해 공동 의결권 및 처분권을 보유하고 있습니다.
주식 수 및 비용 업데이트 외에는 투자 목적이나 발행사와의 계약, 협정, 관계에 변경 사항이 없습니다. 전시물 99.2에는 최근 60일간 실행된 거래 내역이 상세히 기재되어 있으며, 다른 거래는 공개되지 않았습니다.

EcoR1 Capital dépose l'Amendement n°3 au Schedule 13D concernant Galapagos NV (GLPG). Le fonds spéculatif axé sur la biotechnologie et son fondateur Oleg Nodelman déclarent désormais une propriété bénéficiaire de 8 714 522 actions ordinaires/ADS, soit 13,22 % des 65 897 071 actions en circulation (Formulaire 20-F, 31 décembre 2024). La position est concentrée dans EcoR1 Capital Fund Qualified, L.P. (8,19 millions d’actions, 12,43 %) tandis que EcoR1 Capital Fund, L.P. détient 0,52 million d’actions (0,79 %).
Les actions ont été accumulées pour un montant total de 399,4 millions de dollars US ; des frais additionnels de 293 693 dollars US ont été payés à Citibank pour la conversion des ADS en actions ordinaires. EcoR1 et M. Nodelman exercent un pouvoir conjoint de vote et de disposition sur l’intégralité de la participation.
En dehors de la mise à jour des totaux d’actions et des coûts, le dépôt n’apporte aucune modification à l’objectif d’investissement précédemment déclaré ni aux contrats, accords ou relations avec l’émetteur. L’Exhibit 99.2 détaille les transactions effectuées au cours des 60 derniers jours ; aucune autre opération n’a été divulguée.

EcoR1 Capital reicht Änderung Nr. 3 zum Schedule 13D für Galapagos NV (GLPG) ein. Der auf Biotechnologie fokussierte Hedgefonds und sein Gründer Oleg Nodelman melden nun ein wirtschaftliches Eigentum von 8.714.522 Stammaktien/ADS, was 13,22 % der 65.897.071 ausstehenden Aktien entspricht (Formular 20-F, 31. Dezember 2024). Die Position konzentriert sich auf den EcoR1 Capital Fund Qualified, L.P. (8,19 Mio. Aktien, 12,43 %), während der EcoR1 Capital Fund, L.P. 0,52 Mio. Aktien (0,79 %) hält.
Die Aktien wurden für insgesamt 399,4 Millionen US-Dollar erworben; zusätzlich wurden 293.693 US-Dollar Gebühren an Citibank für die Umwandlung von ADS in Stammaktien gezahlt. EcoR1 und Herr Nodelman haben gemeinsames Stimm- und Verfügungsrecht über die gesamte Beteiligung.
Abgesehen von der Aktualisierung der Aktienanzahl und Kosten enthält die Einreichung keine Änderungen am zuvor angegebenen Anlagezweck oder an Verträgen, Vereinbarungen oder Beziehungen mit dem Emittenten. Anlage 99.2 enthält Details zu in den letzten 60 Tagen getätigten Transaktionen; weitere Geschäfte wurden nicht offengelegt.

Positive
  • EcoR1 Capital’s 13.22 % stake demonstrates significant institutional confidence in GLPG.
  • US$399.4 million invested underscores long-term commitment from a biotech-focused fund.
Negative
  • None.

Insights

TL;DR: EcoR1 now controls 13.22 % of GLPG after spending US$399 m; no new activist intentions disclosed.

Impact: The disclosure confirms a sizeable, above-13 % holding by a specialist biotech investor, signalling continued conviction in Galapagos. The amendment mainly reflects share tally updates and ADS conversion fees, with voting power remaining shared among EcoR1 entities and founder Oleg Nodelman. Absence of purpose changes means investors gain transparency on stake size but no fresh strategic clues. Overall, the filing is noteworthy for ownership concentration yet neutral regarding immediate operational or financial effects.

EcoR1 Capital presenta l'Emendamento n. 3 al Modulo 13D riguardante Galapagos NV (GLPG). Il fondo hedge specializzato in biotecnologie e il suo fondatore Oleg Nodelman comunicano ora una partecipazione beneficiaria di 8.714.522 azioni ordinarie/ADS, pari al 13,22% delle 65.897.071 azioni in circolazione (Modulo 20-F, 31 dicembre 2024). La posizione è concentrata principalmente in EcoR1 Capital Fund Qualified, L.P. (8,19 milioni di azioni, 12,43%), mentre EcoR1 Capital Fund, L.P. detiene 0,52 milioni di azioni (0,79%).
Le azioni sono state accumulate per un totale di 399,4 milioni di dollari USA; inoltre, sono stati pagati 293.693 dollari USA in commissioni a Citibank per la conversione degli ADS in azioni ordinarie. EcoR1 e il signor Nodelman detengono il potere condiviso di voto e disposizione sull’intera partecipazione.
Oltre all’aggiornamento delle quantità di azioni e dei costi, il deposito non apporta modifiche allo scopo dell’investimento precedentemente dichiarato né a contratti, accordi o relazioni con l’emittente. L’Exhibit 99.2 dettaglia le operazioni effettuate negli ultimi 60 giorni; non sono state comunicate altre transazioni.

EcoR1 Capital presenta la Enmienda No. 3 al Schedule 13D sobre Galapagos NV (GLPG). El fondo de cobertura enfocado en biotecnología y su fundador Oleg Nodelman reportan ahora una propiedad beneficiaria de 8.714.522 acciones ordinarias/ADS, equivalente al 13,22 % de las 65.897.071 acciones en circulación (Formulario 20-F, 31 de diciembre de 2024). La posición está concentrada en EcoR1 Capital Fund Qualified, L.P. (8,19 millones de acciones, 12,43 %) mientras que EcoR1 Capital Fund, L.P. posee 0,52 millones de acciones (0,79 %).
Las acciones se acumularon por un total de 399,4 millones de dólares estadounidenses; se pagaron además 293.693 dólares en comisiones a Citibank por la conversión de ADS en acciones ordinarias. EcoR1 y el Sr. Nodelman tienen poder compartido de voto y disposición sobre toda la participación.
Además de actualizar los totales de acciones y el costo, la presentación no realiza cambios en el propósito previamente declarado de la inversión ni en contratos, acuerdos o relaciones con el emisor. El Anexo 99.2 detalla las operaciones ejecutadas en los últimos 60 días; no se divulgaron otras transacciones.

EcoR1 Capital이 Galapagos NV(GLPG)에 대해 스케줄 13D 수정안 3호를 제출했습니다. 생명공학 중심의 헤지펀드와 창립자 Oleg Nodelman은 현재 8,714,522 보통주/ADS를 실질 소유하고 있으며, 이는 65,897,071주 발행 주식의 13.22%에 해당합니다(2024년 12월 31일 기준, Form 20-F). 보유 지분은 EcoR1 Capital Fund Qualified, L.P.에 집중되어 있으며(819만 주, 12.43%), EcoR1 Capital Fund, L.P.는 52만 주(0.79%)를 보유하고 있습니다.
주식은 총 3억 9,940만 달러에 매입되었으며, ADS를 보통주로 전환하는 데 Citibank에 추가로 293,693달러의 수수료가 지급되었습니다. EcoR1과 Nodelman 씨는 전체 지분에 대해 공동 의결권 및 처분권을 보유하고 있습니다.
주식 수 및 비용 업데이트 외에는 투자 목적이나 발행사와의 계약, 협정, 관계에 변경 사항이 없습니다. 전시물 99.2에는 최근 60일간 실행된 거래 내역이 상세히 기재되어 있으며, 다른 거래는 공개되지 않았습니다.

EcoR1 Capital dépose l'Amendement n°3 au Schedule 13D concernant Galapagos NV (GLPG). Le fonds spéculatif axé sur la biotechnologie et son fondateur Oleg Nodelman déclarent désormais une propriété bénéficiaire de 8 714 522 actions ordinaires/ADS, soit 13,22 % des 65 897 071 actions en circulation (Formulaire 20-F, 31 décembre 2024). La position est concentrée dans EcoR1 Capital Fund Qualified, L.P. (8,19 millions d’actions, 12,43 %) tandis que EcoR1 Capital Fund, L.P. détient 0,52 million d’actions (0,79 %).
Les actions ont été accumulées pour un montant total de 399,4 millions de dollars US ; des frais additionnels de 293 693 dollars US ont été payés à Citibank pour la conversion des ADS en actions ordinaires. EcoR1 et M. Nodelman exercent un pouvoir conjoint de vote et de disposition sur l’intégralité de la participation.
En dehors de la mise à jour des totaux d’actions et des coûts, le dépôt n’apporte aucune modification à l’objectif d’investissement précédemment déclaré ni aux contrats, accords ou relations avec l’émetteur. L’Exhibit 99.2 détaille les transactions effectuées au cours des 60 derniers jours ; aucune autre opération n’a été divulguée.

EcoR1 Capital reicht Änderung Nr. 3 zum Schedule 13D für Galapagos NV (GLPG) ein. Der auf Biotechnologie fokussierte Hedgefonds und sein Gründer Oleg Nodelman melden nun ein wirtschaftliches Eigentum von 8.714.522 Stammaktien/ADS, was 13,22 % der 65.897.071 ausstehenden Aktien entspricht (Formular 20-F, 31. Dezember 2024). Die Position konzentriert sich auf den EcoR1 Capital Fund Qualified, L.P. (8,19 Mio. Aktien, 12,43 %), während der EcoR1 Capital Fund, L.P. 0,52 Mio. Aktien (0,79 %) hält.
Die Aktien wurden für insgesamt 399,4 Millionen US-Dollar erworben; zusätzlich wurden 293.693 US-Dollar Gebühren an Citibank für die Umwandlung von ADS in Stammaktien gezahlt. EcoR1 und Herr Nodelman haben gemeinsames Stimm- und Verfügungsrecht über die gesamte Beteiligung.
Abgesehen von der Aktualisierung der Aktienanzahl und Kosten enthält die Einreichung keine Änderungen am zuvor angegebenen Anlagezweck oder an Verträgen, Vereinbarungen oder Beziehungen mit dem Emittenten. Anlage 99.2 enthält Details zu in den letzten 60 Tagen getätigten Transaktionen; weitere Geschäfte wurden nicht offengelegt.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The amounts reported include (1) ordinary shares, no par value, of Galapagos NV (the "Issuer") and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer. Based on 65,897,071 ordinary shares outstanding as of December 31, 2024, as reported in the Issuer's Form 20-F filed with the U.S. Securities and Exchange Commission (the "SEC") on March 27, 2025 (the "Form 20-F").


SCHEDULE 13D




Comment for Type of Reporting Person:
The amounts reported include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer. Based on 65,897,071 ordinary shares outstanding as of December 31, 2024, as reported in the Issuer's Form 20-F.


SCHEDULE 13D




Comment for Type of Reporting Person:
The amounts reported include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer. Based on 65,897,071 ordinary shares outstanding as of December 31, 2024, as reported in the Issuer's Form 20-F.


SCHEDULE 13D




Comment for Type of Reporting Person:
The amounts reported include (1) ordinary shares, no par value, of the Issuer and (2) American Depositary Shares, each of which represents one ordinary share, no par value, of the Issuer. Based on 65,897,071 ordinary shares outstanding as of December 31, 2024, as reported in the Issuer's Form 20-F.


SCHEDULE 13D


EcoR1 Capital, LLC
Signature:/s/ Oleg Nodelman
Name/Title:Manager
Date:07/28/2025
Oleg Nodelman
Signature:/s/ Oleg Nodelman
Name/Title:Reporting Person
Date:07/28/2025
EcoR1 Capital Fund Qualified, L.P.
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:07/28/2025
EcoR1 Capital Fund, L.P.
Signature:/s/ Oleg Nodelman
Name/Title:Manager of the General Partner, EcoR1 Capital, LLC
Date:07/28/2025

FAQ

How many Galapagos (GLPG) shares does EcoR1 Capital now own?

EcoR1 and affiliates report 8,714,522 ordinary shares/ADSs.

What percentage of GLPG’s outstanding shares is held by EcoR1?

The holding represents 13.22 % of the 65.9 million shares outstanding.

How much has EcoR1 spent acquiring its GLPG position?

The funds paid an aggregate US$399,380,734.97 for the shares, excluding ADS conversion fees.

Did EcoR1 convert ADSs into ordinary GLPG shares?

Yes, the funds paid US$293,693.40 to Citibank to convert ADSs to ordinary shares.

Does the filing change EcoR1’s stated purpose for investing in Galapagos?

No. The amendment reports ownership updates only; the investment purpose remains unchanged.

What is the CUSIP number for Galapagos ordinary shares?

The CUSIP is 36315X101.
Galapagos Nv

NASDAQ:GLPG

GLPG Rankings

GLPG Latest News

GLPG Latest SEC Filings

GLPG Stock Data

2.19B
65.90M
48.23%
3.29%
Biotechnology
Healthcare
Link
Belgium
Mechelen